Stock 002412 HUNAN HANSEN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hunan Hansen Pharmaceutical Co., Ltd.

Equities

002412

CNE100000PK2

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-06-06 EDT 		5-day change 1st Jan Change
5.44 CNY +3.42% Intraday chart for Hunan Hansen Pharmaceutical Co., Ltd. -7.64% -19.76%
05-29 Hunan Hansen Pharmaceutical's Gets Nod to Make Changes to Iopamidol Injection MT
04-26 Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 4,206 4,413 3,351 3,195 3,085 3,412
Enterprise Value (EV) 1 4,383 4,467 3,426 3,188 2,924 3,252
P/E ratio 28.5 x 27.2 x 31.6 x 23.7 x 18.4 x 16.6 x
Yield - 0.86% - - 4.89% -
Capitalization / Revenue 4.56 x 4.97 x 4.52 x 3.58 x 3.37 x 3.57 x
EV / Revenue 4.75 x 5.03 x 4.62 x 3.57 x 3.19 x 3.4 x
EV / EBITDA 22.7 x 18.9 x 25.2 x 18 x 15.8 x 14.5 x
EV / FCF 39.5 x 70.4 x -74.4 x 64.7 x -113 x 39.9 x
FCF Yield 2.53% 1.42% -1.34% 1.54% -0.89% 2.51%
Price to Book 3.09 x 2.88 x 2.1 x 1.83 x 1.63 x 1.74 x
Nbr of stocks (in thousands) 503,200 503,200 503,200 503,200 503,200 503,200
Reference price 2 8.359 8.770 6.660 6.350 6.130 6.780
Announcement Date 19-04-22 20-04-27 21-04-28 22-04-27 23-04-28 24-04-26
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 921.9 887.5 741.2 891.8 916.1 955.5
EBITDA 1 192.8 235.9 136 177.2 184.6 224
EBIT 1 147.5 188.5 86.08 126.1 133.2 173.2
Operating Margin 16% 21.23% 11.61% 14.14% 14.54% 18.13%
Earnings before Tax (EBT) 1 165.9 188.8 117.6 149.9 181.9 226
Net income 1 147.5 162.4 106.1 134.8 167.6 205
Net margin 16% 18.3% 14.32% 15.12% 18.3% 21.46%
EPS 2 0.2932 0.3227 0.2109 0.2680 0.3331 0.4074
Free Cash Flow 1 110.9 63.48 -46.03 49.24 -25.92 81.48
FCF margin 12.03% 7.15% -6.21% 5.52% -2.83% 8.53%
FCF Conversion (EBITDA) 57.52% 26.91% - 27.78% - 36.37%
FCF Conversion (Net income) 75.16% 39.09% - 36.52% - 39.74%
Dividend per Share - 0.0750 - - 0.3000 -
Announcement Date 19-04-22 20-04-27 21-04-28 22-04-27 23-04-28 24-04-26
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 177 54.2 74.4 - - -
Net Cash position 1 - - - 7.76 161 160
Leverage (Debt/EBITDA) 0.9196 x 0.2298 x 0.5475 x - - -
Free Cash Flow 1 111 63.5 -46 49.2 -25.9 81.5
ROE (net income / shareholders' equity) 11.4% 11.2% 6.79% 8.08% 9.22% 10.6%
ROA (Net income/ Total Assets) 5.27% 6.4% 2.85% 3.94% 3.78% 4.68%
Assets 1 2,800 2,538 3,721 3,421 4,431 4,382
Book Value Per Share 2 2.710 3.040 3.170 3.460 3.760 3.900
Cash Flow per Share 2 0.1600 0.2300 0.2100 0.1800 0.2900 0.1000
Capex 1 64.5 35.7 129 229 11.5 19.5
Capex / Sales 7% 4.02% 17.41% 25.72% 1.26% 2.04%
Announcement Date 19-04-22 20-04-27 21-04-28 22-04-27 23-04-28 24-04-26
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
HUNAN HANSEN PHARMACEUTICAL CO., LTD. Stock Hunan Hansen Pharmaceutical Co., Ltd.
-19.76% 378M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.95% 632B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.16% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 248B
NOVARTIS AG Stock Novartis AG
+11.88% 216B
ROCHE HOLDING AG Stock Roche Holding AG
-0.78% 219B
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002412 Stock
  4. Financials Hunan Hansen Pharmaceutical Co., Ltd.